Dupilumab-associated lymphoid reactions require caution.

A study published in JAMA Dermatology has found that dupilumab, a treatment for atopic dermatitis (AD), can cause a benign reversible lymphoid reaction (LR) that mimics mycosis fungoides (MF), a type of cutaneous T-cell lymphoma. The study recommends careful diagnosis of AD, monitoring of patients on dupilumab for new symptoms, and thorough evaluation of suspicious LRs. The study also highlights the importance of distinguishing between AD and MF, as well as the need for vigilance in ruling out MF in patients on dupilumab. The study suggests that discontinuing dupilumab can lead to resolution of the LR. [Extracted from the article]